NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the proposed transaction, Passage Bio shareholders are expected to own approximately 7% of the combined company. Halper Sadeh encourages Passage Bio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh